HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma
Hypertension-related, calcium-regulated gene (HCaRG/COMMD5) is highly expressed in renal proximal tubules, where it contributes to the control of cell proliferation and differentiation. HCaRG accelerates tubular repair by facilitating re-differentiation of injured proximal tubular epithelial cells,...
Gespeichert in:
Veröffentlicht in: | Oncotarget 2017-09, Vol.8 (41), p.69559-69576 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 69576 |
---|---|
container_issue | 41 |
container_start_page | 69559 |
container_title | Oncotarget |
container_volume | 8 |
creator | Matsuda, Hiroyuki Campion, Carole G Fujiwara, Kyoko Ikeda, Jin Cossette, Suzanne Verissimo, Thomas Ogasawara, Maiko Gaboury, Louis Saito, Kosuke Yamaguchi, Kenya Takahashi, Satoru Endo, Morito Fukuda, Noboru Soma, Masayoshi Hamet, Pavel Tremblay, Johanne |
description | Hypertension-related, calcium-regulated gene (HCaRG/COMMD5) is highly expressed in renal proximal tubules, where it contributes to the control of cell proliferation and differentiation. HCaRG accelerates tubular repair by facilitating re-differentiation of injured proximal tubular epithelial cells, thus improving mouse survival after acute kidney injury. Sustained hyper-proliferation and de-differentiation are important hallmarks of tumor progression. Here, we demonstrate that cancer cells overexpressing HCaRG maintain a more differentiated phenotype, while several of them undergo autophagic cell death. Its overexpression in mouse renal cell carcinomas led to smaller tumor size with less tumor vascularization in a homograft tumor model. Mechanistically, HCaRG promotes de-phosphorylation of the proto-oncogene erythroblastosis oncogene B (ErbB)2/HER2 and epigenetic gene silencing of epidermal growth factor receptor and ErbB3 via promoter methylation. Extracellular signal-regulated kinase, AKT and mammalian target of rapamycin which mediate ErbB-dowstream signaling pathways are inactivated by HCaRG expression. In addition, HCaRG is underexpressed in human renal cell carcinomas and more expressed in normal tissue adjacent to renal cell carcinomas of patients with favorable prognosis. Taken together, our data suggest a role for HCaRG in the inhibition of tumor progression as a natural inhibitor of the ErbB signals in cancer and as a potential prognostic marker for renal cell carcinomas. |
doi_str_mv | 10.18632/oncotarget.18012 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5642500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1954064013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-5def704f63211d4c9bb199e40ce71d9d227b1d19ffe2ffa68b421708a7eab1a83</originalsourceid><addsrcrecordid>eNpVUM9PwjAUboxGCPIHeDE7epm0XbutF41ORBMIidFz03Yd1GwrtoPE_94KiPgO7_f73nsfAJcI3qA8TfDItsp2wi10FxIQ4RPQR4ywGFOanB75PTD0_gMGoSTLMTsHPcwghRjTPrh7LsTrZFTMZ7NHGpl2aaTpfDR28iFyWulVZ11cOrPRbYhbUUdK10EJp0xrG3EBzipRez3c2wF4fxq_Fc_xdD55Ke6nsSIYdzEtdZVBUoW7ESqJYlIixjSBSmeoZCXGmUQlYlWlcVWJNJcEowzmItNCIpEnA3C7w12tZaNLpdvOiZqvnGmE--JWGP6_0polX9gNpynBFMIAcL0HcPZzrX3HG-N_fhGttmvPEaMEpgSiJLSiXaty1nunq8MaBPmWe_7HPd9yH2auju87TPwynXwDHd-Ceg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954064013</pqid></control><display><type>article</type><title>HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma</title><source>Freely Accessible Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Matsuda, Hiroyuki ; Campion, Carole G ; Fujiwara, Kyoko ; Ikeda, Jin ; Cossette, Suzanne ; Verissimo, Thomas ; Ogasawara, Maiko ; Gaboury, Louis ; Saito, Kosuke ; Yamaguchi, Kenya ; Takahashi, Satoru ; Endo, Morito ; Fukuda, Noboru ; Soma, Masayoshi ; Hamet, Pavel ; Tremblay, Johanne</creator><creatorcontrib>Matsuda, Hiroyuki ; Campion, Carole G ; Fujiwara, Kyoko ; Ikeda, Jin ; Cossette, Suzanne ; Verissimo, Thomas ; Ogasawara, Maiko ; Gaboury, Louis ; Saito, Kosuke ; Yamaguchi, Kenya ; Takahashi, Satoru ; Endo, Morito ; Fukuda, Noboru ; Soma, Masayoshi ; Hamet, Pavel ; Tremblay, Johanne</creatorcontrib><description>Hypertension-related, calcium-regulated gene (HCaRG/COMMD5) is highly expressed in renal proximal tubules, where it contributes to the control of cell proliferation and differentiation. HCaRG accelerates tubular repair by facilitating re-differentiation of injured proximal tubular epithelial cells, thus improving mouse survival after acute kidney injury. Sustained hyper-proliferation and de-differentiation are important hallmarks of tumor progression. Here, we demonstrate that cancer cells overexpressing HCaRG maintain a more differentiated phenotype, while several of them undergo autophagic cell death. Its overexpression in mouse renal cell carcinomas led to smaller tumor size with less tumor vascularization in a homograft tumor model. Mechanistically, HCaRG promotes de-phosphorylation of the proto-oncogene erythroblastosis oncogene B (ErbB)2/HER2 and epigenetic gene silencing of epidermal growth factor receptor and ErbB3 via promoter methylation. Extracellular signal-regulated kinase, AKT and mammalian target of rapamycin which mediate ErbB-dowstream signaling pathways are inactivated by HCaRG expression. In addition, HCaRG is underexpressed in human renal cell carcinomas and more expressed in normal tissue adjacent to renal cell carcinomas of patients with favorable prognosis. Taken together, our data suggest a role for HCaRG in the inhibition of tumor progression as a natural inhibitor of the ErbB signals in cancer and as a potential prognostic marker for renal cell carcinomas.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.18012</identifier><identifier>PMID: 29050225</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Research Paper</subject><ispartof>Oncotarget, 2017-09, Vol.8 (41), p.69559-69576</ispartof><rights>Copyright: © 2017 Matsuda et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-5def704f63211d4c9bb199e40ce71d9d227b1d19ffe2ffa68b421708a7eab1a83</citedby><cites>FETCH-LOGICAL-c422t-5def704f63211d4c9bb199e40ce71d9d227b1d19ffe2ffa68b421708a7eab1a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642500/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642500/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29050225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsuda, Hiroyuki</creatorcontrib><creatorcontrib>Campion, Carole G</creatorcontrib><creatorcontrib>Fujiwara, Kyoko</creatorcontrib><creatorcontrib>Ikeda, Jin</creatorcontrib><creatorcontrib>Cossette, Suzanne</creatorcontrib><creatorcontrib>Verissimo, Thomas</creatorcontrib><creatorcontrib>Ogasawara, Maiko</creatorcontrib><creatorcontrib>Gaboury, Louis</creatorcontrib><creatorcontrib>Saito, Kosuke</creatorcontrib><creatorcontrib>Yamaguchi, Kenya</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><creatorcontrib>Endo, Morito</creatorcontrib><creatorcontrib>Fukuda, Noboru</creatorcontrib><creatorcontrib>Soma, Masayoshi</creatorcontrib><creatorcontrib>Hamet, Pavel</creatorcontrib><creatorcontrib>Tremblay, Johanne</creatorcontrib><title>HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Hypertension-related, calcium-regulated gene (HCaRG/COMMD5) is highly expressed in renal proximal tubules, where it contributes to the control of cell proliferation and differentiation. HCaRG accelerates tubular repair by facilitating re-differentiation of injured proximal tubular epithelial cells, thus improving mouse survival after acute kidney injury. Sustained hyper-proliferation and de-differentiation are important hallmarks of tumor progression. Here, we demonstrate that cancer cells overexpressing HCaRG maintain a more differentiated phenotype, while several of them undergo autophagic cell death. Its overexpression in mouse renal cell carcinomas led to smaller tumor size with less tumor vascularization in a homograft tumor model. Mechanistically, HCaRG promotes de-phosphorylation of the proto-oncogene erythroblastosis oncogene B (ErbB)2/HER2 and epigenetic gene silencing of epidermal growth factor receptor and ErbB3 via promoter methylation. Extracellular signal-regulated kinase, AKT and mammalian target of rapamycin which mediate ErbB-dowstream signaling pathways are inactivated by HCaRG expression. In addition, HCaRG is underexpressed in human renal cell carcinomas and more expressed in normal tissue adjacent to renal cell carcinomas of patients with favorable prognosis. Taken together, our data suggest a role for HCaRG in the inhibition of tumor progression as a natural inhibitor of the ErbB signals in cancer and as a potential prognostic marker for renal cell carcinomas.</description><subject>Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVUM9PwjAUboxGCPIHeDE7epm0XbutF41ORBMIidFz03Yd1GwrtoPE_94KiPgO7_f73nsfAJcI3qA8TfDItsp2wi10FxIQ4RPQR4ywGFOanB75PTD0_gMGoSTLMTsHPcwghRjTPrh7LsTrZFTMZ7NHGpl2aaTpfDR28iFyWulVZ11cOrPRbYhbUUdK10EJp0xrG3EBzipRez3c2wF4fxq_Fc_xdD55Ke6nsSIYdzEtdZVBUoW7ESqJYlIixjSBSmeoZCXGmUQlYlWlcVWJNJcEowzmItNCIpEnA3C7w12tZaNLpdvOiZqvnGmE--JWGP6_0polX9gNpynBFMIAcL0HcPZzrX3HG-N_fhGttmvPEaMEpgSiJLSiXaty1nunq8MaBPmWe_7HPd9yH2auju87TPwynXwDHd-Ceg</recordid><startdate>20170919</startdate><enddate>20170919</enddate><creator>Matsuda, Hiroyuki</creator><creator>Campion, Carole G</creator><creator>Fujiwara, Kyoko</creator><creator>Ikeda, Jin</creator><creator>Cossette, Suzanne</creator><creator>Verissimo, Thomas</creator><creator>Ogasawara, Maiko</creator><creator>Gaboury, Louis</creator><creator>Saito, Kosuke</creator><creator>Yamaguchi, Kenya</creator><creator>Takahashi, Satoru</creator><creator>Endo, Morito</creator><creator>Fukuda, Noboru</creator><creator>Soma, Masayoshi</creator><creator>Hamet, Pavel</creator><creator>Tremblay, Johanne</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170919</creationdate><title>HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma</title><author>Matsuda, Hiroyuki ; Campion, Carole G ; Fujiwara, Kyoko ; Ikeda, Jin ; Cossette, Suzanne ; Verissimo, Thomas ; Ogasawara, Maiko ; Gaboury, Louis ; Saito, Kosuke ; Yamaguchi, Kenya ; Takahashi, Satoru ; Endo, Morito ; Fukuda, Noboru ; Soma, Masayoshi ; Hamet, Pavel ; Tremblay, Johanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-5def704f63211d4c9bb199e40ce71d9d227b1d19ffe2ffa68b421708a7eab1a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Matsuda, Hiroyuki</creatorcontrib><creatorcontrib>Campion, Carole G</creatorcontrib><creatorcontrib>Fujiwara, Kyoko</creatorcontrib><creatorcontrib>Ikeda, Jin</creatorcontrib><creatorcontrib>Cossette, Suzanne</creatorcontrib><creatorcontrib>Verissimo, Thomas</creatorcontrib><creatorcontrib>Ogasawara, Maiko</creatorcontrib><creatorcontrib>Gaboury, Louis</creatorcontrib><creatorcontrib>Saito, Kosuke</creatorcontrib><creatorcontrib>Yamaguchi, Kenya</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><creatorcontrib>Endo, Morito</creatorcontrib><creatorcontrib>Fukuda, Noboru</creatorcontrib><creatorcontrib>Soma, Masayoshi</creatorcontrib><creatorcontrib>Hamet, Pavel</creatorcontrib><creatorcontrib>Tremblay, Johanne</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsuda, Hiroyuki</au><au>Campion, Carole G</au><au>Fujiwara, Kyoko</au><au>Ikeda, Jin</au><au>Cossette, Suzanne</au><au>Verissimo, Thomas</au><au>Ogasawara, Maiko</au><au>Gaboury, Louis</au><au>Saito, Kosuke</au><au>Yamaguchi, Kenya</au><au>Takahashi, Satoru</au><au>Endo, Morito</au><au>Fukuda, Noboru</au><au>Soma, Masayoshi</au><au>Hamet, Pavel</au><au>Tremblay, Johanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2017-09-19</date><risdate>2017</risdate><volume>8</volume><issue>41</issue><spage>69559</spage><epage>69576</epage><pages>69559-69576</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Hypertension-related, calcium-regulated gene (HCaRG/COMMD5) is highly expressed in renal proximal tubules, where it contributes to the control of cell proliferation and differentiation. HCaRG accelerates tubular repair by facilitating re-differentiation of injured proximal tubular epithelial cells, thus improving mouse survival after acute kidney injury. Sustained hyper-proliferation and de-differentiation are important hallmarks of tumor progression. Here, we demonstrate that cancer cells overexpressing HCaRG maintain a more differentiated phenotype, while several of them undergo autophagic cell death. Its overexpression in mouse renal cell carcinomas led to smaller tumor size with less tumor vascularization in a homograft tumor model. Mechanistically, HCaRG promotes de-phosphorylation of the proto-oncogene erythroblastosis oncogene B (ErbB)2/HER2 and epigenetic gene silencing of epidermal growth factor receptor and ErbB3 via promoter methylation. Extracellular signal-regulated kinase, AKT and mammalian target of rapamycin which mediate ErbB-dowstream signaling pathways are inactivated by HCaRG expression. In addition, HCaRG is underexpressed in human renal cell carcinomas and more expressed in normal tissue adjacent to renal cell carcinomas of patients with favorable prognosis. Taken together, our data suggest a role for HCaRG in the inhibition of tumor progression as a natural inhibitor of the ErbB signals in cancer and as a potential prognostic marker for renal cell carcinomas.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29050225</pmid><doi>10.18632/oncotarget.18012</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1949-2553 |
ispartof | Oncotarget, 2017-09, Vol.8 (41), p.69559-69576 |
issn | 1949-2553 1949-2553 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5642500 |
source | Freely Accessible Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
subjects | Research Paper |
title | HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A52%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HCaRG/COMMD5%20inhibits%20ErbB%20receptor-driven%20renal%20cell%20carcinoma&rft.jtitle=Oncotarget&rft.au=Matsuda,%20Hiroyuki&rft.date=2017-09-19&rft.volume=8&rft.issue=41&rft.spage=69559&rft.epage=69576&rft.pages=69559-69576&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.18012&rft_dat=%3Cproquest_pubme%3E1954064013%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1954064013&rft_id=info:pmid/29050225&rfr_iscdi=true |